TG Therapeutics, Inc. (TGTX) Stock Overview
Explore TG Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
TG Therapeutics, Inc. (TGTX)
Key Financials
Key Financials
Market Cap
8.3B
P/E Ratio
17.68
EPS (TTM)
$2.76
ROE
0.72%
TGTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of TG Therapeutics, Inc. (NASDAQ: TGTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, TG Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TGTX on the NASDAQ shows an RSI of 50.09, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $44.92 for the NASDAQ listing.
Key metrics behind TG Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of 17.68 and a market capitalization of 8.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TGTX on the NASDAQ.